作者:Tsuyoshi Shinozuka、Kousei Shimada、Satoshi Matsui、Takahiro Yamane、Mayumi Ama、Takeshi Fukuda、Motohiko Taki、Yuko Takeda、Eri Otsuka、Michiko Yamato、Shin-ichi Mochizuki、Keiko Ohhata、Satoru Naito
DOI:10.1016/j.bmc.2006.06.032
日期:2006.10
A novel series of cathepsin K inhibitors derived from Novartis compound I is described. Optimization of the P1, P3, and P1' units led to the identification of 4-aminophenoxyacetic acid 24b with an IC(50) value of 4.8 nM, which possessed an excellent selectivity over other human cathepsins and good pharmacokinetic (PK) properties. Oral administration of compound 24b to ovariectomized (OVX) rats showed
描述了衍生自诺华化合物I的一系列新的组织蛋白酶K抑制剂。P1,P3和P1'单元的优化导致了4-氨基苯氧基乙酸24b的鉴定,其IC(50)值为4.8 nM,与其他人组织蛋白酶相比具有出色的选择性,并具有良好的药代动力学(PK)特性。向卵巢切除的(OVX)大鼠口服给予化合物24b显示出股骨中骨矿物质密度(BMD)改善的趋势。